[Hui Cong Pharmaceutical Industry Network] The 2016 annual report reveals that the drama has come to an end. The rankings of 183 A-share listed pharmaceutical companies (according to the Tongda letter classification pharmaceutical manufacturing sector) are also clear at a glance. Many companies’ net profit is “second killâ€. enterprise. Below, Xinkang will analyze the three major sectors of chemical pharmaceuticals, proprietary Chinese medicines and bio-pharmaceuticals to see where these companies with high net profit are showing growth.
Chemical pharmaceutical company net profit TOP3
Fosun Pharma: net profit of 2.806 billion yuan, an increase of 14.05%
In 2016, Fosun Pharma realized operating income of 14.629 billion yuan, an increase of 16.02% compared with the same period of the previous year; net profit attributable to shareholders of listed companies was 2.806 billion yuan, an increase of 14.05%.
Core products are growing steadily. From the perspective of segmentation business, Fosun's pharmaceutical manufacturing and R&D business achieved operating income of 10.26 billion yuan, up 14.83% from 2015, accounting for 70.27% of operating income; medical service business realized income of 1.678 billion yuan, up 21.67 from 2015. %. In terms of product status, core products in the field of anti-infective diseases, metabolic and digestive diseases, and cardiovascular disease treatments account for the main source of revenue. According to its annual report, in 2016, Fosun Pharma's total sales of 18 single-piece products or series exceeded 100 million yuan, and the sales of products such as Aodejin, Youdil, Cefmetazole, and Atomolan exceeded RMB 5. 100 million yuan.
According to the annual report, during the reporting period, the business of Fosun Pharma Group maintained growth, the sales structure was further optimized, the marketing system construction and supply chain integration effects appeared, and the joint venture Sinopharm Holdings continued to maintain rapid growth.
Hengrui Medicine: net profit of 2.589 billion yuan, an increase of 19.22%
In 2016, Hengrui Pharmaceutical achieved operating income of 11.094 billion yuan, an increase of 19.08% compared with the same period of the previous year; net profit attributable to shareholders of listed companies was 2.589 billion yuan, an increase of 19.22%.
R&D investment continues to grow. According to the data of Hengrui Medicine Annual Report, its research and development expenses reached 1.184 billion yuan in 2016, an increase of 32.82% over the same period of last year, accounting for 10.68% of operating income. As can be seen from the summary of the annual report, Hengrui Medicine's R&D investment ranks in the forefront of the industry. While R&D expenses are increasing, Hengrui's performance is growing steadily, and the growth highlights are no longer limited to anti-tumor drugs: 2016 anti-cancer drug revenue was 4.83 billion yuan, up 25.68% year-on-year; contrast agent income was 1.31 billion yuan, year-on-year. The growth rate was 30.05%; the income from surgical anesthesia products was 3.01 billion yuan, a year-on-year increase of 19.14%.
In addition, the net cash flow from Hengrui Pharmaceutical Investment Activities increased by 2.179 billion yuan from the previous period, mainly due to the increase in cash paid for the purchase and construction of fixed assets and the purchase of bank wealth management products during the reporting period.
Adisseo: net profit of 1.865 billion yuan, an increase of 22.03%
In 2016, Adisseo achieved operating income of 10.688 billion yuan in operating income, down 29.56% compared with the same period of last year; net profit attributable to shareholders of listed companies was 1.865 billion yuan, up 22.03% year-on-year.
The main products performed well. In 2106, Andisu accounted for 27% of the market share of methionine, ranking second in the world. Relying on the growth of global demand, the existing equipment has improved the production capacity of methionine through the bottleneck removal measures, and the sales volume of each product line has been improved. And due to factors such as the exchange rate and the price increase of petroleum derivatives, the income will increase.
Attached:
2016 A-share chemical pharmaceutical companies' 2016 results and net profit
Note: The classification of listed companies is based on Tongdaxin; the data is compiled according to the Eastern Fortune Network, ranked according to the level of net profit margin.
Chinese patent medicine company net profit TOP3
Kangmei Pharmaceutical: net profit of 3.34 billion yuan, an increase of 21.17%
In 2016, Kangmei Pharmaceutical achieved operating income of 21.642 billion yuan, an increase of 19.79% compared with the same period of last year; net profit attributable to shareholders of listed companies was 3.34 billion yuan, an increase of 21.17%.
The status of the pieces is stable. According to the product: Kangmei Pharmaceutical's Chinese medicine decoction revenue was 4.7 billion yuan, up 26.4% year-on-year; Chinese herbal medicine trade was 5.79 billion yuan, down 4.0% year-on-year; drug circulation was 10 billion yuan, up 34% year-on-year; medical equipment was 1.32 billion yuan. Growth of 45%; health food 1.74 billion yuan, an increase of 23.2%. According to its annual report, it is speculated that the main reason for the increase is that the dominant position of the medicine tablets has been stabilized. In 2016, Kangmei Pharmaceutical's Chinese medicine decoction products revenue was 4.704 billion yuan, a year-on-year increase of 26.43%. At the same time, benefiting from the influence of the “two-vote system†and other circulation policies, the revenue of Kangmei Pharmaceutical's pharmaceutical trade pharmaceutical industry in 2016 was 7.301 billion yuan, a year-on-year increase of 35.35%.
Yunnan Baiyao: net profit of 2.92 billion yuan, an increase of 5.38%
In 2016, Yunnan Baiyao achieved operating income of 22.411 billion yuan, an increase of 8.06% year-on-year; net profit of 2.92 billion yuan, an increase of 5.38%.
Great health layout is outstanding. At present, Yunnan Baiyao has expanded its market segments in the field of big health, and has created four business segments including pharmaceuticals (central, transdermal and generic), health-care products, Chinese medicine resources products, and pharmaceutical business. More than 390 varieties of dosage forms. Among them, the main effects of hemostasis, analgesia and swelling and siltification include Yunnan Baiyao Band-Aid, Yunnan Baiyao Aerosol, and Yunnan Baiyao Ointment. The above three products continue to occupy the first place in the Chinese market. Oral care, such as Yunnan Baiyao toothpaste products, sales accounted for 16.49% of the national toothpaste market share, ranking second in the market share of similar products. The results of its large health product echelon have begun to show its effects, such as Qixuekang, which regulates qi and nourish the blood, the Qingyuan hair care series and the æ±² æ±² mask series products, and the Leopard VII, represented by freeze-dried and ultra-fine powder technology. Seventh.
Dong'e Ejiao: net profit of 1.852 billion yuan, an increase of 14%
In 2016, Dong'e Ejiao achieved a revenue of 6.317 billion yuan, a year-on-year increase of 15.92%; the net profit attributable to shareholders of listed companies was 1.852 billion yuan, a year-on-year increase of 14%.
The Ejiao series is the main source of income. In terms of industries, pharmaceutical industry accounted for the largest proportion of revenue. In 2016, pharmaceutical industry revenue was 5.621 billion yuan, accounting for 88.98% of operating income; pharmaceutical business 2016 revenue was 266 million yuan, accounting for 4.21% of operating income. In terms of products, Ejiao series products had a revenue of 5.371 billion yuan in 2016 and a gross profit margin of 74.11%, ranking among the top among Chinese patent medicine companies. Dong'e Ejiao raised the ex-factory price of Ejiao block, Ejiao and Peach Aijiao at 14%, 28% and 25% respectively at the end of 2016. From the sales data of the fourth quarter, the price increase did not cause significant sales decline. Dong'e Ejiao's fourth quarter revenue was 2.332 billion yuan, and net profit was 627 million yuan, a significant increase of 40.10% and 26.52% respectively.
Attached:
2016 A-share Chinese patent medicine companies' 2016 performance and net profit
Note: The classification of listed companies is based on Tongdaxin; the data is compiled according to the Eastern Fortune Network, ranked according to the level of net profit margin.
Biopharmaceutical company net profit TOP3
Shanghai Lai Shi: net profit of 1.613 billion yuan, an increase of 11.84%
In 2016, Shanghai Laishi achieved operating income of 2.326 billion yuan, a year-on-year increase of 15.54%; net profit attributable to shareholders of listed companies was 1.613 billion yuan, an increase of 11.84%; net profit margin reached 69.34%.
Plasma station layout and plasma utilization predominate. According to the Shanghai Lai Shi Annual Report, there are 35 plasma collection stations (including 2 in construction), and the annual pulp collection capacity is nearly 900 tons. Shanghai Lai Shi is one of the few blood product manufacturers in China that can extract six components from plasma. It is also one of the most complete production companies of clotting factor products in the same industry in China. Currently, it has 11 varieties of blood products. , with advantages and competitiveness.
M&A integration drive. In 2014, Shanghai Lai Shi completed the acquisition of Zhengzhou Lai Shi and Tonglu Bio. In 2016, Tongli Bio, a wholly-owned subsidiary, completed the acquisition of a 90% stake in Zhejiang Haikang. Zhengzhou Lai has good experience in the pulping scale, pulping capacity and fine production management of a single pulp station; Tonglu Bio has advantages in pulp station management, product yield and special exemption products; Zhejiang Haikang as Zhejiang Province The only blood products company has a certain geographical advantage. After the merger and acquisition, Shanghai Lai Shi has improved in the management of the pulp station, production management, procurement and sales channel management.
Hualan Bio: net profit of 780 million yuan, an increase of 32.45%
In 2016, Hualan Bio realized operating income of 1.935 billion yuan, a year-on-year increase of 31.45%; net profit attributable to shareholders of listed companies was 780 million yuan, an increase of 32.45%.
Chongqing company is the main performance growth point. Hualan Biotech's blood products revenue in 2016 was 1.814 billion yuan, a rapid growth of 34.03%, of which the static growth rate was 73.28%. Due to the rapid increase in the overall supply of the industry and the changes in distribution channels, the company's albumin growth rate slowed to 6.53%. The growth rate of blood products was 37.56%. Chongqing's 2016 net profit increased by 51.43% year-on-year, which was the most important growth point for the company's performance. Benefiting from the new pulping station, the pulp production volume has increased significantly. In 2016, Chongqing Company's revenue was 730 million yuan, a year-on-year increase of 55.41%, and net profit was 285 million yuan, a year-on-year increase of 51.43%.
The vaccine business has great potential for development. In 2016, Hualan's biological vaccine business achieved an operating income of 108 million and an estimated loss of approximately 45 million. At present, Hualan Biological has obtained clinical trial approvals for four major varieties such as trastuzumab and rituximab. Panitumumab, denizumab and ipilimumab are undergoing preclinical studies.
Biological shares: net profit of 645 million yuan, an increase of 34.36%
In 2016, the company's operating income reached 1.517 billion yuan, a year-on-year increase of 21.7%; the net profit attributable to shareholders of listed companies was 645 million yuan, an increase of 34.36%.
Biopharmaceutical products have higher gross profit. In terms of industries, its biopharmaceutical products revenue was 1.448 billion yuan in 2016, with a gross profit margin of 78.29%; other businesses had revenue of 38 million yuan in 2016. Its main products are excellent performance in foot-and-mouth disease vaccine, brucellosis vaccine and poultry.
Attached:
2016 A-share biopharmaceutical companies' 2016 results and net profit
Note: The classification of listed companies is based on Tongdaxin; the data is compiled according to the Eastern Fortune Network, ranked according to the level of net profit margin.
Photo by: He Simu
Source: Annual reports of listed companies
Editor in charge: Yan Wenqian
Nylon Fabric,Nylon Spandex Fabric,Ripstop Nylon Fabric,Waterproof Nylon Fabric
Suzhou Zhiqin Textile CO.LTD , https://www.zhiqintextile.com